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Bardet–Biedl Syndrome (BBS) is an autosomal recessive,
multisystem, genetically heterogeneous, ciliopathic condition
caused by mutations in multiple genes. Here we sought to
determine if inheritance of a single BBS mutation increased
the risks of frequent disorders of this syndrome such as
obesity, hypertension, and diabetes. Various metabolic and
renal diseases in a cohort of 46 patients with BBS,
prospectively followed for up to 28 years, were compared to
recent assessments of these factors in 96 relatives with a
heterozygote mutation (carriers) and 37 relatives without a
contributing mutation (non-carriers). Ten mutations in 6
genes causing this syndrome were identified in 21 families
from whom DNA was obtained. The body mass index or the
incidences of hypertension, diabetes, or stage 3 chronic
kidney diseases were found to be similar between carriers
and non-carriers but were all significantly less than
those of family members with BBS. Similarly, the median
age of onset of hypertension or diagnosis of stage 3 kidney
disease, or the diagnosis of diabetes by age 70 were all
significantly lower in those with BBS than in gene carriers
or non-carriers. While our study shows that metabolic and
renal events occurred frequently and at an early age in BBS,
the heterozygous inheritance of any of the 10 described BBS
mutations did not predispose family members to obesity,
diabetes, hypertension, or renal impairment.
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The Bardet–Biedl syndrome (BBS) is characterized by retinal
dystrophy, truncal obesity, dystrophic extremities, male
hypogenitalism, and renal abnormalities.1–4 In addition,
defects in most organ systems have been observed, and the
incidence of diabetes mellitus, hypertension and renal
impairment is high.3,5 BBS is a ciliopathy6 caused by
autosomal recessive inheritance of mutations in over 12
genes.6–18 In the general population, obesity, diabetes mellitus,
and hypertension occur frequently, and are considered to
have a complex inheritance.19–21 Chronic kidney disease
(CKD) occurs less frequently but its incidence is also
influenced by genetic factors.22,23
An increase in renal cancers and malformations has been
reported in first-degree relatives of BBS cases.24 A high
proportion (27%) of fathers of BBS cases (obligate carriers of
a BBS mutation) were severely overweight (BMI exceeding
31).25,26 The possibility that haploinsufficiency alone predis-
poses to disease has been investigated in animal models.
Injection of the morpholino-BBS 12, 10 and 6 suppressants
into wild-type zebra fish embryos at progressively increasing
concentrations produced dose-dependent effects on fetal
development, which were rescued by co-injection of a
capped-BBS10 mRNA that escaped morpholino suppression,
suggesting that inheritance of a mutant allele for BBS could
predispose to clinical manifestations in humans.18 In
polycystic kidney disease (a ciliopathy), PKD2 haploinsuffi-
ciency in a mouse model altered intracellular calcium
concentrations in vascular smooth muscle cells in a way that
it was likely to predispose to hypertension.27
Ninety percent of Newfoundlander’s population of about
510,000 has descended from about 30,000 founders.28 Since
its peopling in the late eighteenth century and early
nineteenth centuries, little immigration or outmigration has
occurred. Communities have developed in geographical and
cultural isolation, characterized by large families, a high
coefficient of kinship, and founder effects.29 However, of 12
founder populations, Newfoundland’s is the one most
generalizable to Caucasian populations.30 The prevalence of
BBS in Newfoundland is high (1 in 18,000),3 caused by
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multiple mutations in multiple genes.4,6,9,11 The clinical
manifestations of BBS have been studied in three separate
assessments over 22 years 1,3,5 and investigation of the
molecular genetics has been ongoing.6,9,11,31–34
We have now identified the molecular genetic cause of
BBS in all cases in Newfoundland from whom DNA has been
collected. In addition, we have determined, those first- or
second-degree relatives of cases who are and are not carriers
of a BBS mutation. We have carried out a fourth assessment
of these cases over 28 years of prospective follow-up, and
investigated relatives for the first time. The objectives of this
report are (1) to determine the prevalence of obesity and the
incidence of hypertension, diabetes, and CKD in BBS cases,
in comparison with family members without a BBS
mutation, and (2) to compare the prevalence of obesity
and the incidence of the endocrine/renal events in carriers of
a BBS mutation with that in non-carriers.
RESULTS
Cases of BBS
Forty-six cases from 26 families were identified. Of 153
siblings, 30% had BBS. DNA was obtained from 21 families,
and the molecular genetic cause of the disease was identified
in all cases (Table 1). Ten mutations in six BBS genes were
identified.
Five BBS1 families, homozygous for the M390R mutation,
clustered on the southwest coastal trade route (Figure 1). One
of nine BBS1 cases was a heterozygous carrier of the BBS3
mutation. Cases from two BBS6 families, homozygous for the
D143fsX157 mutation, were from the same bay (Conception
Bay), as were cases from four families with the F94fsX103
mutation. One of the 15 BBS6 cases was a heterozygous
carrier of the BBS1 mutation. However, cases from two
BBS10 families, homozygous for C91fsx95, were from
communities geographically distant from each other (Seal
Cove and Green Bay). Sporadic families with homozygous
Table 1 | BBS families in Newfoundland by mutation
Mutation BBS family identification Case (n=46) Carrier (n=96) Non-carrier of familial mutation (n=37)
BBS1: M390R B7, B8, B10, B15, B19, B23 8 Homozygous 45 18
BBS2: Y24X B14 1 Homozygous 7 2
BBS3: G169A B2 5 Homozygous 2 1
BBS5: IVS6+3A4G B9 5 Homozygous 13 6
BBS6: D143fsX157 B13, B20 4 Homozygous 5 3
BBS6: F94fsX 103 B3, B4, B16, B25 8 Homozygous 13 5
BBS6: D143fsX157/F94fsX103 B1 2 Compound heterozygous 3 1
BBS6: F94fsX103 L227P B5 1 Compound heterozygous 3 1
BBS10: C91fsX95 B21, B12 4 Homozygous 5 0
BBS10: F198 del/ F199 del B6, B11 2 Compound heterozygous 0 0
Unknown/no DNA B17, B18, B22, B24, B26 6 0 0
Total 26 46 96 37
BBS, Bardet–Biedl syndrome.
LABRADOR
NEWFOUNDLAND
BBS1
BBS2
BBS3
BBS4
BBS5
BBS6
BBS10
UNKNOWN
Figure 1 | Geographic distribution of Bardet–Biedl syndrome
(BBS) families by genotype.
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mutations in BBS2, BBS3, and BBS5, and compound
heterozygotes for BBS6 and BBS10, were distributed
randomly around the coast of the island. One of the BBS3
cases was a heterozygous carrier of the BBS1 mutation
At death or at last follow-up, the cases were younger (40.8
years of age) than carriers (53.8 years) and non-carriers (56.8
years). Fifty-seven per cent of cases were male, as were 43% of
carriers and 46% of non-carriers. Of 96 carriers with a BBS
mutation, BBS1 accounted for 47%, BBS2 for 7%, BBS3 for
2%, BBS5 for 14%, BBS6 (through its four different
mutations) for 25%, and BBS10 for 5% (Table 1). In one
BBS1 family (Newfoundland-B10) three members carried
both a BBS1 and BBS3 mutation, none of whom presented
with any of the cardinal manifestations of BBS. These carriers
were categorized according to the homozygous mutation seen
in the BBS cases present in their family (BBS1).
Body mass index
The body mass index (BMI) in adults with BBS was
significantly higher than that of non-carriers (38±12 vs
29±3, respectively Po0.0001). The mean BMI of carriers
and non-carriers were similar (28±6 vs 29±3, respectively).
The proportion of heterozygotes with BMI X31 kg/m2 was
22% (16/74), compared with 23% (7/30) in non-carriers. On
analysis based on genotype, no differences were observed in
either cases or carriers (Table 2).
Hypertension. In cases, 33 of 46 (72%) were diagnosed
with hypertension, all of whom were treated with anti-
hypertensive medication. The median age to onset of
hypertension treatment was 34 years (95% confidence
interval (CI)¼ 31–38) (Figure 2). In comparison with non-
carriers, cases were 7.8 times more likely to develop
hypertension (95% CI¼ 4.1–14.9).
In carriers, 52 of 96 (54%) were diagnosed with
hypertension, of whom 40 (77%) received antihypertensive
medication. The median age to hypertension diagnosis in
carriers was 57 years (95% CI¼ 54–61) and at hypertension
treatment it was 63 years (58–68 years).
In non-carriers, 17 of 35 (49%) were diagnosed with
hypertension, 15 (82%) of whom were treated. The median
age to hypertension diagnosis in non-carriers was 67 years
(95% CI¼ 59–72) and at hypertension treatment it was 67
years (95% CI¼ 59–75). No significant difference was
observed in the incidence of hypertension requiring treat-
ment on comparison of the carriers and non-carriers
(hazards ratio (HR)¼ 1.24, 95% CI 0.68–2.25) (Figure 2).
The mean systolic blood pressure in untreated carriers was
124±14 mm Hg and that in non-carriers it was
119±11 mm Hg. The mean diastolic blood pressure in
carriers and non-carriers was 79±8 mm Hg and
77±8 mm Hg, respectively.
No differences in the incidence of hypertension were
observed when cases and carriers were analyzed by genotype
(Table 2).
Diabetes mellitus
In cases, 23 of 46 (50%) had been diagnosed with diabetes
mellitus, all of whom were treated by insulin, oral
Table 2 | Body mass index and incidence of renal and metabolic events in Bardet–Biedl syndrome (BBS) cases and in carriers of
a BBS mutation, by genotype
BBS1 BBS5 BBS6 All other BBS genotypes
Genotype Carriers Cases Carriers Cases Carriers Cases Carriers Cases
Total n 45 8 13 5 24 15 14 12
BMI adults (kg/m2)
n 38 7 12 5 12 10 11 4
Mean 29.1 36.5 27.5 46.1 27.8 39.5 28.1 35.1
s.d. 5.4 3.4 4.2 17.4 2.6 17.0 9.5 6.6
Systolic blood pressure
untreated (mm Hg)
n 22 7 8 6
Mean 127 123.4 118.5 119
s.d. 13.7 18.1 9.6 12.5
Diastolic blood pressure
untreated (mm Hg)
Mean 81.3 77.7 74.5 75
s.d. 8.7 4.7 10.6 7.8
Diabetes by age 70 (%) 7 50 23 40 8 47 7 58
Hypertension by age 70 (%) 60 88 38 80 37.5 67 57 67
CKD stage 3 by age 70 7 25 8 80 5 36 0 42
BMI, body mass index; CKD, chronic kidney diseases; n=number of subjects for which clinical data were available for the indicated examination.
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hypoglycemic agents, or diet. The median age to diagnosis of
diabetes was 43 years (95% CI 39–48) (Figure 3). There was
an 18-fold increased risk of diabetes in cases compared with
that in non-carriers (95% CI 6.8–48.2).
No significant difference was observed in the incidence of
diabetes comparing carriers and non-carriers (HR¼ 0.71,
95% CI 0.30–1.70). In carriers 16/93 (17%) were diagnosed
with diabetes, of whom 12 (75%) were receiving treatment.
The median age to onset of diabetes mellitus in the carriers
was 75 years.
In non-carriers 8 of 34 (24%) were diagnosed with
diabetes mellitus, of whom 7 (88%) were receiving diabetes
treatment. By age 70, 45% of non-carriers had developed
diabetes (Figure 3). There was no difference in the incidence
of diabetes in cases and carriers of a BBS mutation, when
classified by genotype (Table 2).
Chronic renal failure
In cases of BBS, 20 of 43 (47%) developed chronic renal
failure stage 3. The median age at onset of CKD stage 3 was
58 years (Figure 4). There was a 15.1-fold increased risk of
CKD in cases compared with that in non-carriers (95% CI
5.1–44.8).
Nine of these 20 cases developed stage 4 CKD (estimated
glomerular filtration rate o30 ml/min) and six progressed
to end-stage renal disease. By age 60 years, the cumula-
tive percentage of cases who developed end-stage disease
was 21%.
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Figure 2 | Time to hypertension requiring treatment in
Bardet–Biedl syndrome (BBS) cases, in carriers of a BBS
mutation and in non-carriers.
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Figure 3 | Time to diabetes mellitus in Bardet–Biedl syndrome
(BBS) cases, in carriers of a BBS mutation and in non-carriers.
Non-carrier
1.0
0.8
0.6
0.4
0.2
0.0
0 20 40 60 80 100
Case
D
is
ea
se
-fr
ee
 s
ur
viv
al Carrier
Mutation status Events
At 30 yr At 40 yr
Cumulative %
At 50 yr At 60 yr At 70 yr
Median
age to 
event
Mean age
to event 95% CI
81–91
63–99
53–64
86
81
58
83
77
55100
21
4534
45
60
0
0
2016
0
008
5
20
0
5
Carrier (n=76)
Non-carrier
(n=33)
Age at chronic renal failure or last follow-up
Case (n=43)
Figure 4 | Time to stage 3 chronic kidney disease in
Bardet–Biedl syndrome (BBS) cases, in carriers of a BBS
mutation, and in non-carriers.
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Table 3 shows the renal structural abnormalities identified
after a review of serial renal ultrasounds and intravenous
pyelograms in 37 patients. The mean age at last imaging test
was 38 years (range 1–65). Only 1 (3%) patient had a normal
kidney, 30 (81%) had abnormal (blunted/dilated) calyces, 24
(65%) had cysts/calyceal diverticula, and 27 (73%) had fetal
lobulation.
In all, 17 (46%) patients had imaging test at the time of
diagnosis of stage 3 CKD. This group was substantially older
(mean age 48 years; range 18–65) than those without stage 3
CKD (mean age 30 years; range 1–54). Fifty-three percent
(N¼ 9) of those with stage 3 CKD had diffuse cortical loss in
at least one kidney compared with 10% (N¼ 2) in those
without stage-3 CKD (w2¼ 8.1, P¼ 0.004).
Of 23 cases with BBS who developed diabetes mellitus,
two had stage-3 CKD diagnosed before diagnosis of diabetes,
and 13 subsequently developed CKD, with median time to
CKD being 18 years (95% CI 11.4–24.6 years). In 17 patients
with stage-3 CKD we reviewed diabetes history, renal
ultrasound and urine protein results. Nine (53%) had
diabetes mellitus, which had been present for 3–35 years
(mean 15 years) before diagnosis of stage-3 CKD. Of nine
patients with diffuse cortical loss 3 (33%) had diabetes
mellitus without proteinuria. Of eight patients without
diffuse cortical loss six (75%) had diabetes mellitus, but
only one of these cases had proteinuria with X1 g of
proteinuria on dipstix.
No significant difference was observed in the incidence of
stage-3 CKD on comparing carriers and non-carriers
(HR¼ 0.59, 95% CI 0.19–1.19). In carriers, 8 of 76 (11%)
were diagnosed with stage 3 CKD. The median age of onset of
chronic renal failure was 86 years. In non-carriers, 5 of 33
(15%) were diagnosed with stage 3 CKD, with median age of
onset of 81 years (Figure 4). When analyzed by genotype, no
differences in the incidence of CKD in either carriers or cases
were found (Table 2).
Survival in BBS
Twelve BBS cases died, with the median survival being 63
years (95% CI¼ 62–64). Cumulative mortality at age 40 years
was 12%, at age 50 it was 20%, and at age 60 it was 25%
(Figure 5).
DISCUSSION
BBS is caused by mutations in several different genes. The
biological complexities of the cilium/basal body/centrosome,
which is dependent on multiple genes,6 implies that many
pathogenic BBS mutations may occur. It is likely that some of
the approximately 30,000 founders of the Newfoundland
population carried different heterozygous BBS mutations to
Newfoundland 8–10 generations ago. Their progeny was
exposed to a state of geographical and religious isolation,
which predisposed it to autosomal recessive inheritance of
BBS. In fact, 10 different BBS mutations have been discovered
in the Newfoundland population. Multiple families with the
same BBS homozygous mutations were clustered in specific
genetic isolates. Sporadic families with homozygous muta-
tions of different genes and other families with BBS caused by
compound heterozygous mutations have been identified in
random locations around the island. Thus, it appears that the
genetic complexity of the cilium/basal body/centrosome has
predisposed to multiple mutations in multiple genes, some of
which were brought to Newfoundland by its founders where,
together with the high coefficient of kinship in multiple
Newfoundland isolates, they caused the high incidence of
autosomal recessive BBS in Newfoundland.
It is likely that BBS heterozygotes occur in the general
population. In the region from which BBS1 families
originated (south-west Newfoundland), six (1.5%) BBS1
carriers were identified in a group of 400 people studied.35 In
this study, additional BBS mutations were identified in 3 of
130 (2.3%) relatives and these differed from the mutations
causing BBS in the families.
This study clearly shows that early onset obesity, hyper-
tension, diabetes mellitus, CKD and death are associated
Table 3 | Structural abnormalities observed on review of
serial renal imaging tests of cases with Bardet–Biedl
Syndrome, by presence or absence of stage 3 CKD
Stage 3 CKD eGFR460 ml/min Total
n % n % n %
Abnormal calyces 12 71 18 90 30 81
Cysts/diverticulae 10 59 14 70 24 65
Fetal lobulation 12 71 15 75 27 73
Diffuse cortical
Loss in X1 kidney 9 53 2 10 11 30
X1 Small kidney 8 47 0 0 8 22
Focal cortical loss 1 6 3 15 4 11
Total 17 100 20 100 37 100
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.
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Figure 5 | Survival in Bardet-Biedl syndrome (BBS) cases.
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with BBS. It is possible that the high incidence of gene-
tically complex manifestations, such as hypertension and
diabetes, in BBS cases was influenced by other genetic
influences prevalent in the population. The non-carriers
certainly had a high incidence of hypertension, but obesity
was less prevalent than in cases and the onset of hyperten-
sion, diabetes, and chronic renal disease was substantially
later.
It is likely that primary ciliary dysfunction in BBS
predisposes to the renal and endocrine events reported here.
In normal kidneys, the epithelial cilia are sensory transducers
in a cilium-generated signaling pathway.36 Abnormal ciliary
function leads to cysts, calyceal clubbing, and tubular
defects.2,37,38 Defective expression of BBS proteins could also
lead to permanent changes in cellular properties , which lead
to early-onset kidney dysfunction.37 Although the structural
renal changes characteristic of BBS (fetal lobulation, calyceal
abnormalities, and cysts) occurred in cases with and without
stage-3 CKD, diffuse cortical loss and small size in at least one
kidney were observed significantly more frequently in those
with stage-3 CKD than in those without.
It is possible that early-onset diabetes predisposed to CKD.
However, the majority of cases with CKD had diffuse cortical
loss, and only one case of eight with CKD, but without
diffuse cortical loss, had diabetes with overt proteinuria. As
absence of diffuse cortical loss and presence of overt
proteinuria are characteristic of diabetic nephropathy, we
conclude that CKD in BBS is more likely to be primarily the
result of chronic non-glomerular parenchymal disease caused
by BBS than to being secondary to diabetes.
Cilia have been identified in the exocrine, endocrine, and
ductal cells of the pancreas for many years.38 Ciliary defects
have been associated with acinar-cell atrophy and duct
hyperplasia, and compromised glucose homeostasis.39 BBS
patients are prone to type 2 diabetes and have high insulin
levels,1 suggesting that both obesity and primary pancreatic
disease contribute to insulin resistance. Alstrom’s syndrome
is another autosomal recessive ciliopathy strongly associated
with diabetes and insulin resistance.40
It is not fully understood as to how defective cilia
predispose to obesity. Neuronal cilia-dwelling receptors could
be involved in regulating food intake and overall energy
metabolism. In fact, many neurons that are responsive to the
weight-regulating protein, leptin display somatostatin-3
receptors on their cilia.41 Consequently, dysfunctional cilia
associated with BBS could predispose to dysregulation of
energy metabolism. In addition, cilia have been observed in
fat-storing cells of the liver, in the thyroid, and in the adrenal
glands, defects in which could lead to defective storage of fat
and abnormalities in thermoregulation and metabolic rate.37
The etiology of hypertension in BBS is likely to be
complex. The predisposing factors include primary renal
disease, diabetes mellitus, and obesity, which occur frequently
in BBS. Furthermore, abnormalities in intracellular calcium
signaling in vascular cells caused by ciliopathy may induce
dysregulation of contraction and predispose to hyperten-
sion.27 In addition, an underlying genetic predisposition to
hypertension may cluster in these families.
The heterozygous state is not associated with a predis-
position to these endocrine and renal events, as the
prevalence of obesity and incidence of hypertension, diabetes,
and CKD in BBS mutation carriers are comparable with
that in non-carriers. The observation of similar BMI in
BBS mutation carriers and non-carriers is consistent with
our results from a study of BBS1 genotype in obesity, in the
geographical area where cases caused by BBS1 mutations
were identified.35 The BBS1 mutation was found in the
heterozygous state in 3 of 200 obese individuals and also in 3
of 200 matched non-obese controls.
Our results do not support the hypothesis of Croft et al,26
who suggested that the BBS gene may predispose male
heterozygotes to obesity, because 27% of 34 fathers of BBS
children (obligate heterozygotes) had BMI 431 kg/m2.
Unlike our study, they had no control group of non-carriers.
In fact, in our study 22% of heterozygotes had BMI 431
compared with 23% of non-carriers.
The limitations of this study include small numbers
enrolled in the study, potential ascertainment bias, and
definitions of clinical manifestations, which may provide
higher estimates of disease. However, this is a population-
based study that is likely to have identified most of the cases
who presented with blindness, a clinical manifestation highly
prevalent in BBS. The definitions of disease are less likely to
be a problem in those cases that we have been following up
for 28 years, but may be less reliable in relatives who have
been assessed once. The virtual overlap of time–event curves
suggests that very large numbers of relatives would be
required to disprove our conclusion that the incidence of
endocrine/renal events is similar in carriers and in non-
carriers.
We conclude that the high prevalence of BBS in
Newfoundland is likely to be the result of the high coefficient
of kinship in multiple genetic isolates and the frequency with
which different pathogenic BBS mutations may occur. BBS is
associated with early-onset obesity, hypertension, diabetes
mellitus, and CKD, which may be associated with ciliary
dysfunction in a variety of organs. The heterozygous BBS
state is not associated with an increased risk for these
endocrine and renal events.
METHODS
Recruitment of cases
In 1985–86 32 patients from 17 families were initially studied, having
been identified through the registry of the Canadian National
Institute of The Blind, as a result of their attendance at an Ocular
Genetics Clinic and through subsequent family studies. 1
Subsequently, an additional 14 patients from 9 families were
enrolled, including 1 family from Ontario of Newfoundland parentage
who referred themselves.3 Diagnosis was based on the presence of
retinal dystrophy and on at least three of the cardinal manifestations of
BBS (obesity, dystrophic extremities, renal anomalies, and male
hypogenitalism). Consanguinity was documented in 27% of families
(7/26) and suspected in another 15% (4/26).3
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The protocol-driven assessment in 1985–86 included ophthal-
mology examination, anthropomorphic measurements of hands and
feet, glucose tolerance test and insulin levels, tests of pituitary and
reproductive function, measurement of intelligence, and tests of
renal structure and function.1,2 Further protocol-driven assessments
were carried out in 1993,5 2001,3 and 2008, including medical chart
review, weight, blood pressure, renal structure and function, blood
sugar, and HB A1C. In 2001, anthropomorphic measurements of
head, face, ears and genitalia were undertaken, as were qualitative
assessment of facial dysmorphic features from photographs,
neurological and psychiatric examination, speech assessment, and
disdiadochokinetic tests.3
Recruitment of relatives
Twenty-one of 26 families participated in the gene-discovery
research program, of whom 20 participated in this study.
Participants included siblings and parents of cases, along with
some sibships of parents who requested to be enrolled in the study.
Out of 138 first-degree relatives of cases, 78 participated in the
study, 23 were dead, and 37 did not participate. Of 107 siblings of
parents 55 participated, 24 were dead, and 28 did not participate.
Thus, of 198 living eligible relatives, 67% (N¼ 133) participated in
the study. DNA was obtained from 130, and a further 3 were obligate
carriers. Figure 6 shows the sibships enrolled in the study by
genotype.
Research clinics were organized in the community of each family,
standardized histories, physical examinations, and blood pressure
measurements were undertaken, height and weight were measured,
and blood was taken for serum creatinine, blood urea, blood sugar
and HbA1C, and for DNA extraction. In patients with BBS,
all renal ultrasound and intravenous pyelograms were reviewed,
and reports assessed for the presence of abnormal calyces,
cysts, calyceal diverticula, fetal lobulation, diffuse cortical loss, and
small kidneys.
Mutation detection
A collaborative new gene-discovery program was undertaken
between 1998 and 2004, which led to the discovery of BBS6,11
BBS5 6, and BBS3 genes.9.In addition, mutations causing BBS1 and
BBS2 were identified.31 After the discovery of BBS10, the remaining
four Newfoundland families of unknown genetic etiology were
confirmed by Dr Stoetzel in France to have mutations in BBS10.
DNA was extracted from whole blood by salting out. DNA was
amplified by the polymerase chain reaction (PCR) method and
electrophoresis was carried out. The PCR product was then purified.
Cycle sequencing was undertaken and sequencing products were
precipitated. Sequencing was carried out using the capillary-based
ABI 3130 XL. The resultant sequences were analyzed using the
Mutation Surveyor v3.2 program.
The DNA of 130 family members and of 25 BBS cases was
analyzed for the 10 different mutations present in Newfoundland
BBS families. The mutations are as follows: BBS1: M390R; BBS2:
Y2rX; BBS3: G169A; BBS5: 1VS6þ 3A4G; BBS6: F94fs, D143fs,
A242S, and L227P; BBS10: C91 fs and F198, and 9del. Three family
members were obligate carriers. Of the 1300 mutation analyses that
were carried out on relatives of BBS, 5 (0.38%) did not provide a
conclusive result. Four carriers of BBS had inconclusive results and
the non-carriers had none. None of these five inconclusive analyses
Figure 6 | Sibships in the Bardet–Biedl syndrome (BBS) families by carrier status.
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was for the mutation that was expected to present in the relatives’
family. Of 250 tests in 25 cases there were four inconclusive analyses.
Definitions
BBS. At least four of the cardinal features (retinal dystrophy,
obesity, renal abnormalities, male hypogenitalism, and dystrophic
extremities), or three cardinal manifestations in a sibling of an
affected person who had four cardinal features.3.
Obesity. Body mass index (in kg/m2) was calculated from
height and weight measurements. Obesity was defined as body mass
index 430 kg/m2.
Hypertension. Hypertension was defined as sitting systolic
blood pressure X140 mm Hg or a diastolic blood pressure
X90 mm Hg, or on treatment with antihypertensive medications.
Age at hypertension diagnosis and at hypertension treatment or
last follow-up was identified.
Chronic renal disease. Estimated creatinine clearance was
calculated using the modification of diet in renal disease
formula.42,43 From serial estimated-creatinine clearances, age at
diagnosis of stage-3 CKD (o60 ml/min) or last follow-up was
calculated, and so was the age at starting end-stage renal disease
treatment.
Diabetes mellitus. Patients were considered to be diabetic if
they were treated (diet/oral medications/insulin), or had a
hemoglobin A1C above 6%. Age at diagnosis of diabetes or last
follow-up was obtained.
Analysis. Mean BMI and blood pressure in carriers and non-
carriers were compared using two-tailed Student’s t-test. Cumulative
probability of having an event over time was calculated using
Kaplan–Meier analysis in cases, carriers, and in non-carriers. Cox
regression was carried out for each clinical end point to assess the
hazard in (a) cases with BBS compared with non-carriers and
(b) carriers of a BBS mutation compared with non-carriers. The
exponential of b-coefficient and 95% confidence intervals were
calculated. Statistical significance was P value o0.05. The denomi-
nator used in the calculation of proportions for clinical end points
varied, depending on the number of people available for testing.
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